A sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...

The pessimistic outlook by the rating agency triggered speculation that the Chinese firm may likely sell its stake in the Indian pharma com...

Gland Pharma reported revenues of Rs 3463 and a net profit of Rs 997 crore in FY21. Shares of Gland Pharma rose 1.89% to close at Rs 3360 o...

The fresh issue and the offer for sale together is expected to take the IPO size to around Rs 3,000 crore.

The company may raise up to $800 million or Rs 6,000 crore, a source with the knowledge of the matter said.

Gland Pharma, which is owned 74% by the Chinese major, is seeking a valuation of $3 billion, which is more than twice that of the valuation...

The Fosun Group is amongst China’s largest privately-owned investment conglomerates with interests spanning across pharmaceuticals, real es...

Biologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be t...

Fosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.

Symbiotec has been an acquisition target for other drug makers and PE players after the Indore-based company was put up for sale.

Last year, the government relaxed the foreign investment rules, allowing global companies to acquire up to 74 per cent in local drug makers...

The companies haven’t been formally notified yet of the move, the people said, asking not to be identified because the information is priva...

The deal with Fosun is also an example of the excellence of India’s manufacturing capabilities. It goes with the essence of the Make in Ind...

The deal would be the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd an...

Shanghai Fosun will acquire the shares held by Gland Pharma founders Ravi Penmetsa and his family and PE giant KKR.

Fosun has agreed to acquire 96 percent stake, which includes shares held by founders of Gland Pharma Ravi Penmetsa and family and private e...

Coming from behind in a closely fought race that saw US giant Baxter and private equity fund Advent make firm offers early May, Hong Kong-l...